Clinical Trials Browser

Active not recruiting × relatlimab × Thoracic × Clear all

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

468 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung